Vitamin D promotes human extravillous trophoblast invasion in vitro by Chan, Shiaoyng et al.
 
 
Vitamin D promotes human extravillous trophoblast
invasion in vitro
Chan, Shiaoyng; Susarla, Radhika; Canovas, David; Vasilopoulou, Elisavet; Ohizua, O.;
McCabe, Christopher; Hewison, Martin; Kilby, Mark
DOI:
10.1016/j.placenta.2014.12.021
License:
Other (please specify with Rights Statement)
Document Version
Peer reviewed version
Citation for published version (Harvard):
Chan, S, Susarla, R, Canovas, D, Vasilopoulou, E, Ohizua, O, McCabe, C, Hewison, M & Kilby, M 2015,
'Vitamin D promotes human extravillous trophoblast invasion in vitro', Placenta, vol. 36, no. 4, pp. 403-9.
https://doi.org/10.1016/j.placenta.2014.12.021
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
NOTICE: this is the author’s version of a work that was accepted for publication in Placenta. Changes resulting from the publishing process,
such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document.
Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in
Placenta, DOI: 10.1016/j.placenta.2014.12.021.
Eligibility for repository checked March 2015
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
Accepted Manuscript
Vitamin D promotes human extravillous trophoblast invasion in vitro
S.Y. Chan, R. Susarla, D. Canovas, E. Vasilopoulou, O. Ohizua, C.J. McCabe, M.
Hewison, M.D. Kilby, Professor
PII: S0143-4004(15)00002-8
DOI: 10.1016/j.placenta.2014.12.021
Reference: YPLAC 3131
To appear in: Placenta
Received Date: 6 June 2014
Revised Date: 22 December 2014
Accepted Date: 31 December 2014
Please cite this article as: Chan S, Susarla R, Canovas D, Vasilopoulou E, Ohizua O, McCabe C,
Hewison M, Kilby M, Vitamin D promotes human extravillous trophoblast invasion in vitro, Placenta
(2015), doi: 10.1016/j.placenta.2014.12.021.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
1 
 
 
Vitamin D promotes human extravillous trophoblast invasion in vitro  1 
SY Chan#a, R Susarla#a, D Canovasa, E Vasilopouloua, O Ohizuab, CJ McCabec, M 2 
Hewisonc, MD Kilbya,d  3 
#Joint first authors who have contributed equally to the manuscript 4 
aCentre for Women’s & Children’s Health and the School of Clinical and 5 
Experimental Medicine, College of Medical and Dental Sciences, University of 6 
Birmingham, Edgbaston, Birmingham, B15 2TT, UK.  7 
bWomen, Children and Sexual Health Directorate, Walsall Hospitals NHS Trust, 8 
Walsall, WS2 9PS, UK.  9 
cCentre for Endocrinology, Diabetes and Metabolism, and the School of Clinical and 10 
Experimental Medicine, College of Medical and Dental Sciences, The University of 11 
Birmingham, Birmingham, B15 2TT, UK. 12 
dFetal Medicine Centre, Birmingham Women’s NHS Foundation Trust, Edgbaston, 13 
Birmingham, B15 2TG, UK. 14 
Corresponding author: Professor MD Kilby 15 
Address: Academic Department, Level 3, Birmingham Woman’s NHS Foundation 16 
Trust, Metchley Park Road, Edgbaston, Birmingham B15 2TG, UK. 17 
Email: m.d.kilby@bham.ac.uk 18 
Telephone: +44 121 627 2778 19 
Word count: 3075 20 
Funding: This study was supported by Action Medical Research (#1949 to MDK, 21 
SYC).  22 
Competing interest(s): The authors have no conflicts of interest to disclose. 23 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
2 
 
 
Abbreviations 24 
 1,25-D3, 1,25-dihydroxyvitamin D3; 25-D3, 25-hydroxyvitamin D3; CK-7, cytokeratin 25 
7; CVS, chorionic villous sampling; CYP24A1, 24-hydroxylase; CYP27B1, 1α-26 
hydroxylase; EVT, extravillous trophoblast; FGR, fetal growth restriction; HLA-G, 27 
human leukocyte antigen G; MMP, matrix metalloproteinase; PBS, phosphate 28 
buffered saline; RT-PCR, reverse transcriptase polymerase chain reaction; uNK, 29 
uterine natural killer cells; VDR, vitamin D receptor.  30 
31 
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Abstract 32 
Introduction: Incomplete human extravillous trophoblast (EVT) invasion of the 33 
decidua and maternal spiral arteries is characteristic of pre-eclampsia, a condition 34 
linked to low maternal vitamin D status. It is hypothesized that dysregulated vitamin 35 
D action in uteroplacental tissues disrupts EVT invasion leading to malplacentation.  36 
Methods: This study assessed the effects of the active vitamin D metabolite, 1,25-37 
dihydroxyvitamin D3 (1,25-D3), and its precursor, 25-hydroxyvitamin D3 (25-D3), on 38 
primary human EVT isolated from first trimester pregnancies. Expression of EVT 39 
markers (cytokeratin-7, HLA-G), the vitamin D-activating enzyme (CYP27B1) and 40 
1,25-D3 receptor (VDR) was assessed by immunocytochemistry. EVT responses 41 
following in vitro treatment with 1,25-D3 (0-10nM) or 25-D3 (0-100nM) for 48-60h 42 
were assessed using quantitative RT-PCR (qRT-PCR) analysis of key target genes. 43 
Effects on EVT invasion through Matrigel® were quantified alongside zymographic 44 
analysis of secreted matrix metalloproteinases (MMPs). Effects on cell viability were 45 
assessed by measurement of MTT.  46 
Results:  EVT co-expressed mRNA and protein for CYP27B1 and VDR, and 47 
demonstrated induction of mRNA encoding vitamin D-responsive genes, 24-48 
hydroxylase (CYP24A1) and cathelicidin following 1,25-D3 treatment. EVT could 49 
respond to 1,25-D3 and 25-D3, both of which significantly increased EVT invasion, 50 
with maximal effect at 1nM 1,25-D3 (1.9-fold; p<0.01) and 100nM 25-D3 (2.2-fold; 51 
p<0.05) respectively compared with untreated controls. This was accompanied by 52 
increased pro-MMP2 and pro-MMP9 secretion. The invasion was independent of cell 53 
viability, which remained unchanged.  54 
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Discussion: These data support a role for vitamin D in EVT invasion during human 55 
placentation and suggest that vitamin D-deficiency may contribute to impaired EVT 56 
invasion and pre-eclampsia. 57 
Key words 58 
Vitamin D; pre-eclampsia; placenta; extravillous trophoblast; cell invasion 59 
60 
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Introduction 61 
Vitamin D-deficiency, defined as a serum concentration of 25-hydroxyvitamin D (25-62 
D3; the main circulating form of vitamin D) less than 50nM, and vitamin D-63 
insufficiency (25-D3<75nM) are especially prevalent in pregnancy. These complicate 64 
at least 67% of pregnancies, particularly in women with darker skin pigmentation, in 65 
various geographical locations around the world [1-4]. A recent meta-analysis of 66 
observational studies noted associations between vitamin D-deficiency in pregnancy 67 
with increased risk of pre-eclampsia, gestational diabetes, preterm birth and small for 68 
gestational age infants; with pre-eclampsia showing the strongest association with an 69 
odds ratio of 2.09 (95%CI 1.50-2.90) [5].  70 
Pre-eclampsia, a syndrome of maternal hypertension, proteinuria and endothelial 71 
dysfunction, affects up to 8% of pregnancies and remains a leading cause of maternal 72 
and perinatal morbidity and mortality [6]. In one study, maternal serum 73 
concentrations of 25-D3 in prospectively collected samples in early pregnancy were 74 
found to be significantly lower in women who subsequently developed pre-eclampsia 75 
[7]. However, the pathogenic mechanisms linking low vitamin D levels with pre-76 
eclampsia are not understood and a causative link between the two remains 77 
controversial. The prevalence of vitamin D insufficiency and incidence of pre-78 
eclampsia are both increased in Black and South Asian women, which may implicate 79 
potential confounding variables associated with ethnicity.  80 
The human hemochorial placenta is an extra-renal tissue with high expression of the 81 
vitamin D-activating enzyme 1α-hydroxylase (CYP27B1), which converts 25-D3 to 82 
active 1,25-dihydroxyvitamin D3 (1,25-D3). Both CYP27B1 and the receptor for 1,25-83 
D3 (VDR) are expressed in human decidua and the villous placenta, with higher 84 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
6 
 
 
expression during the first and second trimesters of pregnancy. This suggests a role 85 
for vitamin D in decidualisation and uteroplacental remodelling [8]. 86 
Cytotrophoblast within the villous placenta differentiates into extravillous trophoblast 87 
(EVT), which has an invasive phenotype. EVT invades the decidua and maternal 88 
spiral arteries from the first trimester until 24 weeks of gestation. This invasion is 89 
critical to maternal spiral artery remodelling and promotion of maternal placental 90 
blood flow to establish effective maternal-fetal exchange. Impairment of this process 91 
predisposes a pregnancy to uteroplacental insufficiency and a significantly increased 92 
risk of pre-eclampsia and fetal growth restriction (FGR). 93 
We hypothesized that vitamin D insufficiency during pregnancy may lead to 94 
dysregulation of placental morphological development, and thus the development of 95 
malplacentation disorders including pre-eclampsia and FGR. Vitamin D has been 96 
demonstrated to regulate inflammation in human decidual uterine natural killer (uNK) 97 
cells [9], which in turn is postulated to impact on the invasion of fetal-derived EVT in 98 
a paracrine manner [10]. In this study, we have now investigated the direct effects of 99 
1,25-D3 and 25-D3 upon isolated human first trimester primary EVT in vitro.  100 
Methods 101 
Ethical approval 102 
Human samples were collected with informed written consent and with the approval 103 
of the South Birmingham Research Ethics committee (Reference: 06/Q2707/12) and 104 
the Research and Development office of the Walsall Manor Hospitals NHS Trust 105 
(Project code: 2007013OG(W); approval number: 11070745).  106 
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Sample collection 107 
Placental samples were obtained from women undergoing elective surgical 108 
termination of apparently uncomplicated pregnancies. Samples were collected from 8-109 
11 completed weeks of gestation as determined by ultrasound measurement of crown 110 
rump length prior to pregnancy termination. The fetuses were not known to have 111 
abnormal karyotypes nor structural anomalies.  112 
Cell isolation and culture 113 
Following collection, placental tissues were dissected free and washed three times 114 
with PBS. Primary EVTs were isolated using a method of enzyme digestion followed 115 
by percoll separation as previously described [11]. Characterization of these cells by 116 
immunocytochemistry for EVT markers using anti-cytokeratin 7 (Novocastra, 117 
Newcastle-upon-Tyne, UK; 1:20) and anti-HLA-G (Serotec, Oxford, UK; 1:200) with 118 
an avidin-biotin peroxidase method (Vectastatin Elite kit, Vector Laboratories, 119 
Peterbotough, UK) confirmed 95% purity (Figure 1A-C). Cells were cultured on 120 
growth factor-reduced Matrigel® matrix (BD Biosciences, Erembodegem, Belgium) in 121 
DMEM:F12 medium containing 10% FBS, 1000U/ml penicillin, 1 mg/ml 122 
streptomycin, 2 mM L-glutamine and 1.5 µg/ml amphoteracin B (all reagents from 123 
Gibco Life Technologies, Paisley, UK) in standard 5% CO2 in an air incubator at 124 
37°C. These cells were treated with 1,25-D3 (Enzo Life Sciences, Exeter, UK) at 125 
concentrations of 0-10 nM or with 25-D3 (Enzo Life Sciences) at 0-100 nM. 126 
Incubations were for 48h or 60h as defined in previously reported studies [12]. 127 
Inhibition of CYP27B1 was carried out by pre-treatment for 2h with the pan-128 
cytochrome P450 inhibitor, ketoconazole (Sigma-Aldrich, Dorset, U.K), at 10-5M, 129 
before culture with or without 25-D3 treatment for 60h.  130 
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Immunofluorescence microscopy 131 
Isolated EVT cells were grown (60h) on chamber slides coated with poly-D-lysine 132 
(100µl/well of 0.1mg/ml) and immunofluorescent-stained as described previously 133 
[13]. Cells were co-stained for VDR (clone D-6, Santa Cruz Biotechnology) and 134 
CYP27B1 (Clone H-90, Santa Cruz Biotechnology) (Figure 1). VDR and CYP27B1 135 
were detected using anti-mouse Alexa Fluor 488 (Green) and anti-rabbit Texas Red 136 
(Red) secondary antibodies (Life Technologies) respectively. All antibodies were 137 
used at 1:100 dilution. Slides were mounted with Vectashield™ containing DAPI 138 
(Vector Laboratories Inc., Peterborough, UK) and examined using a fluorescent 139 
microscope (Carl Zeiss, Hertfordshire, UK).  140 
Quantitative RT-PCR 141 
Total RNA was extracted using TRI reagent (Sigma-Aldrich, Dorset, U.K.) following 142 
recovery of cells from Matrigel Matrix using BD cell recovery solution (BD 143 
Biosciences, Bedford, UK) according to the manufacturer’s instructions. Total RNA 144 
(1µg) was reverse transcribed using Avian Myeloblastosis Virus (AMV) reverse 145 
transcriptase (Promega, Southampton, UK) following the manufacturer’s guidelines. 146 
Expression of mRNA encoding CYP27B1 (Hs01096154_m1), CYP24A1 147 
(Hs00167999_m1), VDR (Hs00172113_m1) or cathelicidin (Hs01011707_g1) was 148 
determined and normalized to the expression of 18S rRNA (4319413E), an internal 149 
control in multiplex reactions, using the ABI PRISM 7500 Sequence Detection 150 
System (ABI, Foster City, USA). All primer and probes were produced by Applied 151 
Biosystems, Paisley, UK. Quantification of gene expression was determined using the 152 
∆Ct method described previously [14]. Relative mRNA expression for each sample 153 
was compared with the mean gene expression at the lowest vitamin D dose at which 154 
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expression was detectable, with this being assigned the arbitrary value of 1 within 155 
each experiment.  156 
Invasion assays 157 
Primary EVT were seeded in cell culture inserts for 24-well plates [8µm membrane 158 
pore size (BD Biosciences)] coated with growth factor-reduced Matrigel® matrix 159 
(10µl; BD Biosciences). Invaded cells (assessed in duplicate) were fixed in ethanol, 160 
stained with Mayer's hematoxylin and eosin (Sigma-Aldrich, Dorset, UK), and 161 
counted across the entire membrane at 20X magnification using a light microscope 162 
[11]. The invasion index was expressed as the ratio of invaded cells in the 163 
experimental group relative to the control group (0nM) within each experiment. 164 
Matrix metalloproteinase (MMP) quantification by zymography 165 
Levels of secreted MMP2 and MMP9 protein, which are key gelatinases in the 166 
degradation of the basement membrane by EVT during invasion, were assessed using 167 
gelatin zymography as described previously [15]. Briefly, total protein (16-20 µg) 168 
from EVT-conditioned medium was resolved by electrophoresis in a 12% SDS-PAGE 169 
gel and then incubated (30 min) in zymograph-renaturing buffer followed by 170 
zymograph-developing buffer (Invitrogen, Renfrew, UK) overnight at 37°C before 171 
staining with Coomassie Brilliant Blue R250. Dried gels were then scanned and 172 
densitometry of pro-MMP9 and pro-MMP2 performed using Image J software. 173 
Although active MMP2 was detectable, poor resolution of bands precluded 174 
quantification by relative densitometry. 175 
MTT assays  176 
Cells were seeded in 96 well plates and experiments performed with three or four 177 
replicates of each dose using the quantitative colorimetric 3-(4,5-dimethyldiazol-2-178 
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yl)-2,5 diphenyl Tetrazolium Bromide (MTT; Sigma-Aldrich, Dorset, U.K) assay of 179 
mitochondrial metabolism, as described previously [16]. Within each experiment, the 180 
absorbance values were normalized to the values obtained with no vitamin D 181 
treatment (0nM), which was given an arbitrary value of 100%.  182 
Statistical analysis 183 
Data were analyzed using the SigmaStat v3.1 statistical software (Systat Software Inc, 184 
California, USA). Repeated measures one-way analysis of variance was performed 185 
followed by Tukey all pairwise multiple comparisons post-hoc tests. Data sets passed 186 
the normality test except for the quantitative RT-PCR and pro-MMP2 data, which 187 
required logarithmic transformation prior to statistical analysis. Statistical significance 188 
was taken as p<0.05.  189 
Results 190 
EVT express a functional vitamin D intracrine system and respond to 1,25-D3 and 191 
25-D3 192 
Isolated EVT from first trimester placentae demonstrated coincident protein 193 
expression of the vitamin D-activating enzyme CYP27B1 and the intracellular 194 
receptor for 1,25-D3, VDR (Figure 1D-G), confirming previous quantitative RT-PCR 195 
and immunohistochemistry findings in intact decidual tissue sections [8]. Expression 196 
of mRNA encoding CYP27B1 and VDR (Figure 2A-B) in isolated EVT was 197 
unaffected by treatment with 25-D3 or 1,25-D3, consistent with previous reports in 198 
primary cultures of first trimester human chorionic villous sampling (CVS) specimens 199 
[17]. The co-expression of CYP27B1 and VDR indicate the presence of a potential 200 
EVT vitamin D intracrine system.  201 
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Expression of mRNA encoding the vitamin D feedback catabolic enzyme CYP24A1, 202 
which attenuates vitamin D responsiveness by converting 1,25-D3 and 25-D3 to less 203 
active metabolites, was undetectable in untreated EVT (Figure 2C). This is consistent 204 
with the CYP24A1 gene being methylation-silenced as previously reported in term 205 
villous placenta and in first trimester cytotrophoblast [17]. However, CYP24A1 206 
mRNA expression was induced in EVT treated with 1nM 1,25-D3. Treatment with a 207 
higher concentration of 1,25-D3 (10nM) resulted in a 9-fold increase in CYP24A1 208 
mRNA expression compared to 1nM-treated EVT (p<0.01; Figure 2C). This 209 
magnitude of response in EVT is similar to the 10-fold increase reported in CVS cells 210 
treated with 100nM 1,25-D3, but this magnitude is still significantly less than those in 211 
the hundreds reported in cells in which CYP24A1 is not methylation-silenced [17]. 212 
Evidence that human EVT is vitamin D-responsive was further demonstrated by a 213 
dose-dependent induction of mRNA encoding the vitamin D–responsive antibacterial 214 
protein, cathelicidin, by 1,25-D3 (ANOVA p<0.001; Figure 2D). Messenger RNA 215 
encoding cathelicidin increased by 217-fold and 457-fold with 1nM and 10nM of 216 
1,25-D3 treatment respectively (both p<0.001). These data are consistent with 217 
previous findings in human term placental explants and isolated primary 218 
cytotrophoblast treated with 1,25-D3 [18]. 219 
Effects of 1,25-D3 and 25-D3 on EVT invasion 220 
Treatment of human primary EVT with 1,25-D3 significantly increased directly 221 
quantified cell invasion into Matrigel® (ANOVA p<0.01; Figure 3A). A peak invasion 222 
response was demonstrated at 1nM 1,25-D3, with a 1.9-fold increase in the number of 223 
invaded cells compared with untreated controls (p<0.01). Compared with untreated 224 
EVT, a statistically significant increase in invasion by 1.7-fold (p<0.05) was also 225 
noted with a lower dose of 0.1nM 1,25-D3 but not at a higher dose of 10nM 1,25-D3. 226 
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The diminished response at 10nM 1,25-D3 could be due to preceptor regulation and 227 
inactivation of 1,25-D3 by increased CYP24A1 expression. 228 
Primary EVT also responded to 25-D3, confirming the efficacy of the CYP27B1/VDR 229 
intracrine system. There was a dose-dependent increase in EVT invasion with rising 230 
25-D3 concentrations (ANOVA p<0.05; Figure 3B). A similar magnitude in the peak 231 
response, as seen with 1,25-D3, of a 2.2-fold rise in the number of invaded cells at 232 
100nM 25-D3 compared to controls (p<0.05) suggests that both forms of vitamin D 233 
use a similar response pathway in the promotion of EVT invasion. 234 
To confirm that this observed increase in EVT invasion is mediated by vitamin D, 235 
EVT were pre-treated with a cytochrome P450 inhibitor, ketoconazole [19], prior to 236 
25-D3 treatment. Ketoconazole by itself did not inhibit invasion of EVT, but when 237 
CYP27B1 activity was blocked by ketoconazole the pro-invasive effects of 25-D3 was 238 
significantly attenuated (ANOVA p<0.01; Figure 3C), suggesting that intracellular 239 
EVT metabolism of 25-D3 mediates EVT invasion. 240 
Enhanced Matrigel® invasion by EVT with vitamin D treatment was paralleled by 241 
increased secretion of pro-MMP2 and pro-MMP9 (Figures 4A-4D). Pro-MMP2 242 
increased significantly (ANOVA p<0.001; Figure 4C) with 1,25-D3 at 1nM (p<0.001) 243 
and 10nM (p<0.001), and pro-MMP9 was increased significantly (ANOVA p<0.05; 244 
Figure 4D) with 100nM 25-D3, compared with untreated EVT (p<0.05). 245 
Effects of 1,25-D3 and 25-D3 on EVT cell viability 246 
To confirm that the observed increase in EVT invasion with vitamin D reflected 247 
increased invasive capability rather than enhanced cell proliferation and/or survival, 248 
we assessed EVT cell viability. Data from MTT analyses showed no significant 249 
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change in EVT cell viability following treatment with 1,25-D3 or 25-D3 (Figures 4E-250 
F).  251 
Discussion 252 
Vitamin D deficiency in pregnancy has been associated with an increased risk of pre-253 
eclampsia [7, 20], but the underlying mechanisms are unclear. We have demonstrated 254 
that the vitamin D metabolites, 1,25-D3 and 25-D3, have a direct pro-invasive effect 255 
on isolated human EVT in vitro,  highlighting an entirely novel action for vitamin D 256 
in the placenta. Furthermore, pro-invasive responses to vitamin D suggest that 257 
attenuated EVT invasion of uterine decidua and vasculature, may be one of the 258 
mechanisms by which vitamin D deficiency contributes to the increased risk of pre-259 
eclampsia and FGR. 260 
The pathogenesis of pre-eclampsia is proposed to be a two-stage process: the first 261 
stage occurring in the first and early second trimesters of pregnancy involving 262 
impaired EVT invasion and maternal spiral artery remodelling (malplacentation), and 263 
the second stage occurring after 20 weeks of gestation when the clinical syndrome of 264 
hypertension and proteinuria manifests associated with vascular endothelial 265 
dysfunction [21]. Maternal factors (genetic, behavioural, environmental) interact with 266 
events at both stages, and also influence the link between the first and second stages, 267 
leading to variable pre-eclampsia phenotypes, which are likely to require different 268 
preventive strategies and treatment [21].  269 
Studies where maternal circulating 25-D3 was measured at a time coinciding with the 270 
beginning of the critical maternal vascular remodelling process, have shown 271 
conflicting results, with one study associating low 25-D3 with subsequent 272 
development of pre-eclampsia [7], but with two other studies showing no association 273 
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[22, 23]. However, one of these latter studies did report a significant association 274 
between low circulating 25-D3 at 24-26 weeks gestation with pre-eclampsia in a 275 
predominantly white population with pre-existing risk factors for pre-eclampsia [22]. 276 
These discrepancies may be due to studies using different assay methodology, 277 
different populations of various ethnic mix and risk factors for pre-eclampsia, being 278 
underpowered, to the lack of differentiation between the various manifestations of 279 
pre-eclampsia and failure to account for disruptions in vitamin D metabolism within 280 
the local uteroplacental environment. 281 
Malplacentation, which is characteristically associated with pre-eclampsia, may also 282 
result in fetal growth restriction (FGR). Interestingly, women with severe early onset 283 
pre-eclampsia who also delivered small for gestational age babies had lower 284 
circulating 25-D3 compared with pre-eclamptic women with appropriately grown 285 
babies [24]. Furthermore, independent of maternal hypertension, FGR has also been 286 
associated with lower maternal serum 25-D3 concentrations [25]. All of this supports 287 
the hypothesis that vitamin D deficiency is an etiological factor in the first stage of 288 
pre-eclampsia pathogenesis and in malplacentation.  289 
Furthermore, given the relatively high expression of the activating CYP27B1 in the 290 
placenta [8], local uteroplacental concentrations of the active metabolite, 1,25-D3, 291 
may not reflect the prevailing concentration of 25-D3 in the maternal circulation. In 292 
pre-eclampsia there is additional disruption of the placental vitamin D system with 293 
reports of reduced CYP27B1 activity in primary villous trophoblasts [26], thus 294 
potentially exacerbating the effects of low maternal circulating vitamin D 295 
concentrations or contribute to pre-eclampsia risk despite normal circulating 25-D3 296 
concentrations. Vitamin D may also be implicated in the development of the second 297 
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stage of pre-eclampsia pathophysiology as vitamin D deficient rodents display 298 
endothelial vasodilator dysfunction and hypertension [27, 28] although data from 299 
human studies are conflicting [29, 30].  300 
In this study, a significant pro-invasive effect of 25-D3 was only demonstrable at an 301 
optimal maternal circulatory concentration of 100nM although at lower 25-D3 doses 302 
an insignificant trend suggestive of dose-dependent increased EVT invasion with 303 
rising 25-D3 concentrations was observed. The pro-invasive effect of 1,25-D3 in EVT 304 
is in contrast to previous reports of an anti-invasive effect of 1,25-D3 in several 305 
human cancer cell lines including the human breast cancer cell line MDA-MB-231 306 
[31], human prostate cancer cell lines [32], Lewis lung carcinoma cells [33] and 307 
murine squamous carcinoma cells [34]. Similarly, 1,25-D3 inhibited MMP2 and 308 
MMP9 activity in human primary uterine fibroid cells and the immortalized HuLM 309 
fibroid cell line [35]. The specific differences in human EVT cell characteristics 310 
which lead to differential invasion responses to vitamin D treatment are unknown and 311 
warrant further investigation. With our methodology, despite the high purity of 312 
primary EVT cultures, there remains the possibility that uncharacterized non-EVT 313 
invasive cell types could have made a minor contribution to the population of invaded 314 
cells. Although increased pro-MMP2 and pro-MMP9 secretion was associated with 315 
the EVT invasion promoted by vitamin D, attribution of a direct causative role for 316 
MMP in the mechanism of effect requires further study. 317 
In addition to a direct vitamin D effect on EVT themselves, indirect paracrine effects 318 
on invasion could also occur through vitamin D regulation of cytokine secretion by 319 
neighbouring decidual uNK cells [9] and villous trophoblasts [36]. Thus, in vivo, EVT 320 
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invasion is tightly regulated at multiple levels and the summation of vitamin D effects 321 
at all of these levels is an area for further research. 322 
Apart from EVT invasive capacity, vitamin D may also impact on other events in 323 
placental development such as angiogenesis [37], immune regulation [9, 36] and 324 
enhanced hormone synthesis [38, 39] through autocrine and paracrine mechanisms.  325 
In conclusion, we present in vitro experimental evidence that supports a direct role for 326 
vitamin D in human EVT function. We have provided evidence which suggests that 327 
improved vitamin D status through supplementation early in pregnancy or prior to 328 
conception may therefore be a potential strategy for reducing the risk of pre-eclampsia 329 
and FGR through adequate EVT invasion during the critical phase of placentation 330 
occurring in the first half of gestation. Indeed, a retrospective study of maternal 331 
supplementary intake of vitamin D demonstrated a 27% reduction in the incidence of 332 
pre-eclampsia [40] and a pooled analysis of trials suggested protective effects of 333 
supplementation on low birth weight [41].  334 
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Figure legends 467 
Figure 1: Expression of an intracrine vitamin D system in primary EVT.  468 
(A-C) Immunocytochemistry using an avidin-biotin peroxidase method for the EVT 469 
markers (A) cytokeratin 7 (CK-7) and (B) HLA-G, with (C) control performed with 470 
omission of primary antibody. (D-K) Immunofluorescence microscopy of (D) the 471 
intracellular vitamin D receptor (VDR), (E) the vitamin D-activating enzyme 472 
(CYP27B1), (F) DAPI only, with a merged image (G) in primary EVT from first 473 
trimester human placentae. Control images are of experiments with omission of the 474 
primary antibody with (H) Alexa Fluor 488 (Green) or (I) Texas Red (Red) secondary 475 
antibodies, with the corresponding DAPI-stained and merged images (J and K 476 
respectively). Images were captured using the Axiovision Software (Carl Zeiss, 477 
Hertfordshire, UK). 478 
Figure 2: Effect of 1,25-D3 on expression of mRNA for CYP27A1, VDR, 479 
CYP24A1 and cathelicidin in primary EVT. Relative expression of mRNA 480 
encoding: (A) CYP27B1; (B) VDR; (C) 24-hydroxylase (CYP24A1); (D) cathelicidin 481 
in human first trimester primary EVT. Mean mRNA expression at the lowest vitamin 482 
D dose at which expression was detectable was assigned the arbitrary value of 1. Bars 483 
represent mean + SEM from three different EVT isolates. Statistical significance are 484 
indicated by ** p<0.01, *** p<0.001.   485 
Figure 3: Effect of 1,25-D3 and 25-D3 on Matrigel® invasion by primary EVT. 486 
Effect of treatment with increasing concentrations of: (A) 1,25-D3 for 48 hours; (B)  487 
25-D3 for 60 hours on human first trimester primary EVT. For invasion through 488 
growth factor-reduced Matrigel® the number of invaded EVT cells in each experiment 489 
was normalized to the average number of invaded cells in the control group (0 nM) 490 
and expressed as a percentage of control. (C) Increased invasion of EVT by 25-D3 491 
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(100 nM) is inhibited by ketoconazole (KC; 10-5M), a cytochrome P450 inhibitor.  492 
Bars represent mean data from EVT isolated from eleven (A) or six (B) or three (C) 493 
different pregnancies respectively ± SEM. Statistically significant differences 494 
compared to control (0nM) are indicated by *p<0.05, **p<0.01. 495 
Figure 4: Effect of 1,25-D3 and 25-D3 on primary EVT secretion of matrix 496 
metalloproteinase (MMP) and EVT cell viability. (A and B) Representative gel 497 
zymograph from one experiment showing bands representing pro-MMP9 (92kDa), 498 
pro-MMP2 (72kDa) and active MMP2 (63kDa) in conditioned media from culture of 499 
primary human EVT following treatment with: (A) 1,25-D3 or (B) 25-D3. (C and D) 500 
Relative densitometry of pro-MMP2 and pro-MMP9 following treatment with: (C) 501 
1,25-D3 or (D) 25-D3. Results were normalized to their respective controls (0 nM) 502 
within each experiment. Bars represent the mean ± SEM (C: n=5; D: n=6). 503 
Statistically significant differences compared to control (0nM) are indicated by 504 
*p<0.05, ***p<0.001. (E and F) EVT cell viability was assessed using MTT assays. 505 
Within each experiment data were compared to no treatment (0 nM), which was given 506 
an arbitrary value of 100%. Absorbance is expressed as the difference between 507 
absorbance at OD 570nm and 690nm (background). Bars represent the mean ± SEM 508 
(A: n=6; B: n=5). Although the overall ANOVA on the cell viability data for 25-D3 509 
was statistically significant (p<0.05), further analysis by post-hoc tests failed to 510 
identify any statistically significant differences between the different 25-D3 511 
concentrations. 512 
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Highlights 
• Human primary extravillous trophoblast (EVT) is vitamin D responsive.  
• Vitamin D directly promotes the invasion of primary EVT through Matrigel®. 
• Maternal vitamin D deficiency may thus lead to malplacentation and pre-eclampsia.  
 
 
